



Peter S. Chin, MD, MSHS
Vice President of Late Clinical
Denali Therapeutics

Peter recently joined Denali Therapeutics as Vice President of Late Clinical, leading late-stage clinical development and medical affairs activities.

Previously, Peter was Group Medical Director for Neuroscience in US Medical Affairs at Genentech. He has held clinical development and medical affairs leadership roles at Genentech/Roche, Novartis and now Denali, contributing substantially to the development and evidence-based clinical use of new therapeutics for neurological conditions. Peter has also engaged in advancing clinical research platforms through initiatives sponsored by NIH-NINDS, European Medicines Agency, C-PATH, and various academic-industry consortia, and he has served as a peer reviewer for several neurological journals and for the scientific meeting of the American Academy of Neurology.

Peter completed his BA in Molecular and Cell Biology from the University of California at Berkeley, MD at Dartmouth, neurology residency at the University of Washington, and fellowship as a Robert Wood Johnson Foundation Clinical Scholar at UCLA, where he also obtained an MS in Health Services Research through the School of Public Health.

He currently serves as a Trustee for Bloodworks Northwest.